One Stop Solution For In-Depth Market Research Reports

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Europe Ovarian Cancer Diagnostics and Therapeutics Market

Europe Ovarian Cancer Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Product Code : MDHC00122288
Survey : Mordor Intelligence
Publish On : 12, August, 2022
Category : Healthcare and Pharmaceuticals
Study Area : North America (U.S. and Others), Europe (Germany, France, U.K. and Others), Asia-Pacific (Japan, China, India and Others), Rest of World (Brazil, Rest of Latin America, Middle East & Others)
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6750 / Question Form
Enterprise User USD9000 / Question Form
 - Amneal Pharmaceuticals LLC
- Astrazeneca plc
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Company
- Eli Lilly and Company
- F. Hoffman-La Roche Ltd
- Glaxosmithkline Plc
- Johnson and Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- Siemens Healthineers AG

[Report Description]

The major factors that drive the European ovarian cancer diagnostics and therapeutics market are increasing geriatric women population, rise in ovarian cancer cases, and greater use of combination therapies for the treatment of ovarian cancer. The incidences of ovarian cancer are high in women, who are aged between 55-64 years. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. As per Cancer Research UK, ovarian cancer is the fifth most common cancer in Europe for females. Moreover, as per Globocan estimates, Europe recorded 67,771 new ovarian cancer cases in 2018, with 44,576 deaths. With the rising burden of cancer, there is a rising need for effective treatment. Hence, owing to these factors, the market is expected to witness significant growth over the forecast period.

Key Market Trends

Chemotherapy is Expected to Hold Largest Share of the Europe Ovarian Cancer Diagnostics and Therapeutics Market

Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a certain area, but chemotherapy works throughout the whole body. This means chemotherapy can kill and damage cancer cells that have spread to other parts of the body, which are far away from the original tumor. Chemotherapy-based drugs have been the choice of treatment over decades and have been the main treatment option for several types of cancer. Hence, owing to the above-mentioned factors, along with the rising burden of ovarian cancer, the market for chemotherapy is expected to grow during the forecast period.

Competitive Landscape

The European ovarian cancer diagnostics and therapeutics market consists of several major players. The companies are implementing certain strategic initiatives, such as mergers and acquisitions, new product launches, and partnerships that help them in strengthening their market position. For instance, in 2019, Bristol-Myers Squibb Company has acquired Celgene, which has widened the company’s pipeline in oncology, hematology, immunology, and cardiovascular disease.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format

  • 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Ovarian Cancer
4.2.2 Greater Use of Combination Therapies for the Treatment of Ovarian Cancer
4.2.3 Rising Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Accurate Diagnosis of Ovarian Cancer
4.4 Porter s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Cancer Type
5.1.1 Epithelial Ovarian Tumors
5.1.2 Ovarian Germ Cell Tumors
5.1.3 Others
5.2 By Modality
5.2.1 Diagnosis Biopsy Blood Tests Ultrasound PET CT Scan Other Diagnosis
5.2.2 Therapeutics Chemotherapy Radiation Therapy Immunotherapy Hormonal Therapy Others
5.3 Geography
5.3.1 Europe Germany United Kingdom France Italy Spain Rest of Europe

6.1 Company Profiles
6.1.1 Amneal Pharmaceuticals LLC
6.1.2 Astrazeneca plc
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 Bristol Myers Squibb Company
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffman-La Roche Ltd
6.1.7 Glaxosmithkline Plc
6.1.8 Johnson and Johnson (Janssen Pharmaceuticals)
6.1.9 Pfizer Inc.
6.1.10 Siemens Healthineers AG


Shibuya data count

Shibuya Data Count is a reseller offering a variety of market research reports from different industries, provided by a global team of experienced research professionals who ensure the most reliable and up-to-date research analysis reports.

Recommended reports